Day: November 3, 2022

On July 31, 2020, Shibutani, Masatsune; Nagahara, Hisashi; Fukuoka, Tatsunari; Iseki, Yasuhito; Wang, En; Okazaki, Yuki; Kashiwagi, Shinichiro; Maeda, Kiyoshi; Hirakawa, Kosei; Ohira, Masaichi published an article.Computed Properties of 65-71-4 The title of the article was Combining bevacizumab with trifluridine/thymidine phosphorylase inhibitor improves the survival outcomes regardless of the usage history of bevacizumab in front-line treatment of patients with metastatic colorectal cancer. And the article contained the following:

The efficacy of trifluridine/thymidine phosphorylase inhibitor (FTD/TPI) plus bevacizumab as later-line treatment for metastatic colorectal cancer (mCRC) has been demonstrated. However, little is known about the impact of a usage history of bevacizumab in front-line treatment on the clin. benefit of combining bevacizumab with FTD/TPI. A total of 62 patients with mCRC treated with FTD/TPI±bevacizumab was enrolled and assessed for chemotherapeutic efficacy and adverse events. Regardless of the usage history of bevacizumab in front-line treatment, the FTD/TPI plus bevacizumab group had a significantly better progression-free survival rate than the FTD/TPI monotherapy group, and no significant differences in the safety profile were observed between the two groups. Combining bevacizumab with FTD/TPI improves the survival outcomes with manageable toxicity, regardless of the usage history of bevacizumab in front-line treatment, in patients with mCRC. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Computed Properties of 65-71-4

The Article related to metastatic colorectal cancer bevacizumab trifluridine thymidine phosphorylase inhibitor survival, ftd/tpi, tas-102, bevacizumab, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Computed Properties of 65-71-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On July 31, 2019, Luan, Yunpeng; Li, Yanmei; Yue, Xiaoguan; Cao, Yong; Xiang, Fei; Mao, Dechang; Xiong, Zhi published an article.Quality Control of 5-(Hydroxymethyl)pyrimidine-2,4(1H,3H)-dione The title of the article was Metabonomics of mice intestine in Codonopsis foetens induced apoptosis of intestine cancer cells. And the article contained the following:

Intestinal cancer is a disease with high morbidity and high mortality in China. Previous studies have shown that Codonopsis foetens can inhibit cellular autophagy and promote the apoptosis of intestine cancer cells. Based on metabolomics method coupled with liquid chromatog.-mass spectrometry (LC-MS) technol., we aimed to analyze intestinal small mol. metabolites in the intestinal cancer model group and the Codonopsis foetens treated group. Principal component anal. (PCA) and Partial Least Squares (PLS-DA) were used to identify the pattern of the data. And the metabolic characteristics of the cancer model group were explored based on the metabolic differences between the groups. Multivariate statistical anal. revealed that metabolites presented with differences included: Acetamide, Phosphoric acid, Hydrogen sulfite, Pyruvic acid, Cytosine, 2-Hydroxypyridine, Phosphoric acid, Uracil, Gamma-Aminobutyric acid, Glycerol alpha-monochlorohydrin, Thiosulfic acid, L-Valine, Cysteamine, Taurine, Creatine, Homocysteine, Hypoxanthine, Se-Methylselenocysteine, 5-Hydroxymethyluracil, Oxoglutaric acid, LysoPC(20:0), LysoPC(22:4(7Z,10Z,13Z,16Z)), LysoPC(18:2(9Z,12Z)), LysoPC(16:1(9Z)), LysoPE(0:0/16:0), LysoPE(0:0/18:2(9Z,12Z)), LysoPE(18:0/0:0), LysoPE(20:1(11Z)/0:0), etc. Combined with metabolic pathway anal., pathways presented with differences included: Citrate cycle (TCA cycle), ABC transporters, 2-Oxocarboxylic acid metabolism, Taurine and hypotaurine metabolism, Butanoate metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis, Biosynthesis of amino acids, Protein digestion and absorption, Aminoacyl-tRNA biosynthesis, C5-Branched dibasic acid metabolism, GABAergic synapse, Proximal tubule bicarbonate reclamation, Mineral absorption, Phenylalanine metabolism The results showed that the proliferation of intestinal cancer cells caused cell metabolism disorders, manifesting as changes in metabolic pathways and resulting in changes in metabolites. The experimental process involved the reaction of 5-(Hydroxymethyl)pyrimidine-2,4(1H,3H)-dione(cas: 4433-40-3).Quality Control of 5-(Hydroxymethyl)pyrimidine-2,4(1H,3H)-dione

The Article related to codonopsis metabonomic apoptosis intestine cancer cell, codonopsis foetens, intestinal cancer, metabolic pathway, metabolites, metabonomics, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Quality Control of 5-(Hydroxymethyl)pyrimidine-2,4(1H,3H)-dione

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On July 31, 2020, Tabernero, Josep; Alsina, Maria; Shitara, Kohei; Doi, Toshihiko; Dvorkin, Mikhail; Mansoor, Wasat; Arkenau, Hendrik-Tobias; Prokharau, Aliaksandr; Ghidini, Michele; Faustino, Catia; Gorbunova, Vera; Zhavrid, Edvard; Nishikawa, Kazuhiro; Ando, Takayuki; Yalcin, Suayib; Van Cutsem, Eric; Sabater, Javier; Skanji, Donia; Leger, Catherine; Amellal, Nadia; Ilson, David H. published an article.Electric Literature of 65-71-4 The title of the article was Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS. And the article contained the following:

Abstract: Background: In TAGS, an international, double-blind, phase 3 trial, trifluridine/tipiracil significantly improved overall survival and progression-free survival compared with placebo in heavily pretreated metastatic gastric cancer patients. This paper reports pre-specified quality of life (QoL) outcomes for TAGS. Methods: Patients were randomized 2:1 to trifluridine/tipiracil (35 mg/m2 twice daily on days 1-5 and 8-12 of each 28-day cycle) plus best supportive care (BSC) or placebo plus BSC. QoL was evaluated at baseline and at each treatment cycle, using the EORTC QLQ-C30 and EORTC QLQ-STO22 questionnaires; results were considered valid for anal. only if ≥ 10% of patients completed the questionnaires. Key QoL outcomes were mean changes from baseline and time to deterioration in QoL. A post hoc anal. assessed the association between QoL and time to deterioration of Eastern Cooperative Oncol. Group performance score (ECOG PS) to ≥ 2. Results: Of 507 randomized patients, 496 had baseline QoL data available. The anal. cut-off was 6 cycles for trifluridine/tipiracil and 3 cycles for placebo. In both treatment groups, there were no clin. significant deteriorations in the mean QLQ-C30 Global Health Status (GHS) score, or in most subscale scores. In a sensitivity anal. including death and disease progression as events, there was a trend towards trifluridine/tipiracil reducing the risk of deterioration of QoL scores compared with placebo. Deterioration in the GHS score was associated with deterioration in ECOG PS. Conclusion: QoL was maintained in TAGS, and there was a trend towards trifluridine/tipiracil reducing the risk of QoL deterioration compared with placebo. Trial registration ClinicalTrials.gov number: NCT02500043. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Electric Literature of 65-71-4

The Article related to trifluridine tipiracil anticancer agent gastric cancer metastasis, gastric cancer, health-related quality of life, phase 3, trifluridine/tipiracil, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Electric Literature of 65-71-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On April 30, 2020, Moriwaki, Toshikazu; Fukuoka, Shota; Masuishi, Toshiki; Takashima, Atsuo; Kumekawa, Yosuke; Kajiwara, Takeshi; Yamazaki, Kentaro; Esaki, Taito; Makiyama, Akitaka; Denda, Tadamichi; Hatachi, Yukimasa; Suto, Takeshi; Sugimoto, Naotoshi; Enomoto, Masanobu; Ishikawa, Toshiaki; Kashiwada, Tomomi; Oki, Eiji; Komatsu, Yoshito; Tsuji, Akihito; Tsuchihashi, Kenji; Sakai, Daisuke; Ueno, Hideki; Tamura, Takao; Yamashita, Kimihiro; Shimada, Yasuhiro published an article.Recommanded Product: 5-Methylpyrimidine-2,4(1H,3H)-dione The title of the article was Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study. And the article contained the following:

This study aimed to develop a prognostic scoring system for evaluating the overall survival (OS) benefit. Methods: Patients included in the REGOTAS study, which comprised 489 patients (regorafenib group: 199; FTD/TPI group: 290 patients), were evaluated. OS was analyzed using multivariate Cox proportional model. The prognostic score was calculated using the worst four individual factors weighted by hazard ratio, and the total scores were categorized as low-, moderate-, and high-OS benefit. Results: The worst four factors in the regorafenib group were AST > 40 IU/dL (point, + 3), CRP ≥ 1.0 mg/dL (+ 2), number of metastatic organ site ≥ 3 (+ 2), and duration from initiation of 1st-line chemotherapy < 18 mo (+ 2), while they were AST (+ 2), CRP (+ 2), CA19-9 > 37.0 U/mL (+ 2), and ECOG PS ≥ 1 (+ 2) in the FTD/TPI group. These corresponded to a total prognostic score of > 5, 2-4, and 0 points in the regorafenib group and 8, 2-6, and 0 points in the FTD/TPI group. The median OS in the low, moderate, and high OS benefit group was 3.3 (95% CI 3.0-3.7), 8.1 (95% CI 6.4-9.7), and 12.6 mo (95% CI 10.6-14.6) in the regorafenib group and 2.8 (95% CI 2.0-3.5), 7.5 (95% CI 6.6-8.3), and 15.4 mo (95% CI 9.7-21.2) in the FTD/TPI group. Conclusion: These prognostic scores are useful for identifying patients with mCRC who will obtain survival benefits from these drugs. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Recommanded Product: 5-Methylpyrimidine-2,4(1H,3H)-dione

The Article related to colorectal cancer prognosis regorafenib trifluridine tipiracil, colorectal cancer, prognostic factor, regorafenib, tas-102, trifluridine/tipiracil, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Recommanded Product: 5-Methylpyrimidine-2,4(1H,3H)-dione

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Fujii, Hironori; Matsuhashi, Nobuhisa; Kitahora, Mika; Takahashi, Takao; Hirose, Chiemi; Iihara, Hirotoshi; Yamada, Yunami; Watanabe, Daichi; Ishihara, Takuma; Suzuki, Akio; Yoshida, Kazuhiro published an article in 2020, the title of the article was Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study.Application In Synthesis of 5-Methylpyrimidine-2,4(1H,3H)-dione And the article contains the following content:

TAS-102 is effective for treating patients with metastatic colorectal cancer (mCRC). This study determined whether combining bevacizumab (Bmab) with TAS-102 improves clin. outcomes in refractory mCRC. We retrospectively analyzed data from Japanese patients with refractory mCRC who received TAS-102 (35 mg/m2, twice a day) with (T-B group) or without Bmab (TAS-102 monotherapy; T group) between July 2014 and Dec. 2018. The primary endpoint was median overall survival (OS), and secondary endpoints were median time to treatment failure, overall response rate, and the incidence of adverse events. Clin. outcomes were compared using propensity score matched anal. Data from 57 patients were analyzed (T-B group: 21 patients, T group: 36 patients). Median OS was significantly longer in the T-B group than the T group (14.4 mo vs. 4.5 mo, p < .001). Cox proportional hazard anal. showed that combination therapy with Bmab was significantly correlated with OS. Propensity score matched anal. confirmed that the median OS was significantly longer in the T-B group than the T group (14.4 mo vs. 6.1 mo, p = .006) and that there was a significant correlation between Bmab and OS. The incidence of hypertension (grade ≥2) as an adverse event was significantly higher in the T-B group than the T group (23.8% vs. 0.0%, p = .005), whereas other adverse events were comparable between the two groups. Treatment with Bmab in combination with TAS-102 is significantly associated with improved clin. outcomes in patients with mCRC refractory to standard therapies. Combining bevacizumab (Bmab) with TAS-102 significantly improved overall survival and several prognostic indicators in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies, with manageable toxicities. Treatment with Bmab in combination with TAS-102 is significantly associated with improved clin. outcomes in patients with mCRC. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Application In Synthesis of 5-Methylpyrimidine-2,4(1H,3H)-dione

The Article related to bevacizumab tas102 anticancer agent metastatic colorectal cancer, bevacizumab, colorectal neoplasms, drug-related adverse reactions, survival, trifluridine, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Application In Synthesis of 5-Methylpyrimidine-2,4(1H,3H)-dione

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On January 31, 2020, Yoshino, T.; Cleary, J. M.; Van Cutsem, E.; Mayer, R. J.; Ohtsu, A.; Shinozaki, E.; Falcone, A.; Yamazaki, K.; Nishina, T.; Garcia-Carbonero, R.; Komatsu, Y.; Baba, H.; Argiles, G.; Tsuji, A.; Sobrero, A.; Yamaguchi, K.; Peeters, M.; Muro, K.; Zaniboni, A.; Sugimoto, N.; Shimada, Y.; Tsuji, Y.; Hochster, H. S.; Moriwaki, T.; Tran, B.; Esaki, T.; Hamada, C.; Tanase, T.; Benedetti, F.; Makris, L.; Yamashita, F.; Lenz, H.-J. published an article.Recommanded Product: 65-71-4 The title of the article was Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials. And the article contained the following:

The phase II J003 (N = 169) and phase III RECOURSE (N = 800) trials demonstrated a significant improvement in survival with trifluridine (FTD)/tipiracil (TPI) vs. placebo in patients with refractory metastatic colorectal cancer. This post hoc anal. investigated pharmacokinetic data of FTD/TPI exposure and pharmacodynamic markers, such as chemotherapy-induced neutropenia (CIN) and clin. outcomes. A total of 210 patients from RECOURSE were enrolled in this substudy. A limited sampling approach was used, with three pharmacokinetic samples drawn on day 12 of cycle 1. Patients were categorized as being above or below the median area under the plasma concentration-time curve (AUC) for FTD and TPI. We conducted a post hoc anal. using the entire RECOURSE population to determine the correlations between CIN and clin. outcome. We then carried out a similar anal. on the J003 trial to validate the results. In the RECOURSE subset, patients in the high FTD AUC group had a significantly increased CIN risk. Analyses of the entire population demonstrated that FTD/TPI-treated patients with CIN of any grade in cycles 1 and 2 had significantly longer median overall survival (OS) and progression-free survival (PFS) than patients who did not develop CIN and patients in the placebo group. Patients who required an FTD/TPI treatment delay had increased OS and PFS vs. those in the placebo group and those who did not develop CIN. Similar results were obtained in the J003 cohort. In RECOURSE, patients with higher FTD drug exposure had an increased CIN risk. FTD/TPI-treated patients who developed CIN had improved OS and PFS vs. those in the placebo group and those who did not develop CIN. Similar findings were reported in the J003 cohort, thus validating the RECOURSE results. The occurrence of CIN may be a useful predictor of treatment outcomes for FTD/TPI-treated patients.NCT01607957 (RECOURSE).JapicCTI-090880 (J003). The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Recommanded Product: 65-71-4

The Article related to metastatic colorectal cancer neutropenia survival trifluridine tipiracil, ftd/tpi, j003, recourse, chemotherapy-induced neutropenia, metastatic colorectal cancer, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Recommanded Product: 65-71-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Oki, Eiji; Makiyama, Akitaka; Miyamoto, Yuji; Kotaka, Masahiko; Kawanaka, Hirofumi; Miwa, Keisuke; Kabashima, Akira; Noguchi, Tomohiro; Yuge, Kotaro; Kashiwada, Tomomi; Ando, Koji; Shimokawa, Mototsugu; Saeki, Hiroshi; Akagi, Yoshito; Baba, Hideo; Maehara, Yoshihiko; Mori, Masaki published an article in 2021, the title of the article was Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial.Recommanded Product: 5-Methylpyrimidine-2,4(1H,3H)-dione And the article contains the following content:

A previous Phase I/II study demonstrated that TAS-102 (trifluridine/tipiracil) plus bevacizumab has encouraging efficacy and controllable safety for patients with previously treated metastatic colorectal cancer. Therefore, we designed for assessing efficacy and safety of FTD/TPI plus Bev in elderly patients with previously untreated metastatic colorectal cancer. Treatment consisted of FTD/TPI plus Bev given every 4 wk. Primary endpoint was progression-free survival, assuming null hypothesis of PFS of 5 mo. Secondary endpoints were the overall survival, overall response rate, and adverse events. Between 5 Jan. 2017 and 13 March 2018, 39 patients were enrolled from 18 institutions. Median patient age was 76.0 years (range, 70-88); the ECOG-PS was 0 in 24 patients and 1 in 15 patients. Median PFS was 9.4 mo as a primary endpoint, and the median OS was 22.4 mo. The ORR was 40.5% and the disease control rate was 86.5%. Grade 3-4 AEs included neutropenia, leukopenia, anorexia, febrile neutropenia, and fatigue. FTD/TPI plus Bev is effective and well-tolerated regimen for elderly patients with previously untreated metastatic colorectal cancer. Capecitabine/bevacizumab can be selected as subsequent maintenance therapy without irinotecan and oxaliplatin because FTD/TPI has no cross-resistance with 5-fluorouracil. Clin. trial registration, UMIN clin. trials registry (UMIN000025241). The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Recommanded Product: 5-Methylpyrimidine-2,4(1H,3H)-dione

The Article related to metastatic colorectal cancer trifluridine tipiracil bevacizumab phase ii, trifluridine, bevacizumab, colorectal cancer, elderly, thymidine phosphorylase inhibitor, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Recommanded Product: 5-Methylpyrimidine-2,4(1H,3H)-dione

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On January 31, 2017, Zimin, Yu. S.; Borisova, N. S.; Timerbaeva, G. R.; Gimadieva, A. R.; Mustafin, A. G. published an article.Synthetic Route of 626-48-2 The title of the article was Preparation, Toxicity, and Anti-Inflammatory Activity of Complexes of Uracil Derivatives with Polyfunctional Acids. And the article contained the following:

Uracil derivatives (6-methyluracil, 5-hydroxy-6-methyluracil) and polyfunctional acids (citrus pectin, oxidized fraction of citrus pectin, and 5-aminosalicylic acid) were shown to form rather stable 1:1 complexes, i.e., one uracil mol. for each carboxylic acid of the polyfunctional acid. Synthetic methods for these complexes were developed based on the results. Their toxicity and anti-inflammatory activity were studied. It was established that complexes of 6-methyluracil with the oxidized fraction of citrus pectin and of 5-hydroxy-6-methyluracil with 5-aminosalicylic acid possessed low toxicity and high anti-inflammatory activity. The experimental process involved the reaction of 6-Methylpyrimidine-2,4(1H,3H)-dione(cas: 626-48-2).Synthetic Route of 626-48-2

The Article related to uracil derivative complexation toxicity antiinflammatory, Pharmacology: Effects Of Inflammation Inhibitors and Immune Agents and other aspects.Synthetic Route of 626-48-2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On August 5, 2021, Saulnier, Mark George; Chen, Jesse Jingyang; Karra, Srinivasa; Sprott, Kevin Tyler; Wiles, Jason Allan; Ray, Soumya published a patent.SDS of cas: 785777-98-2 The title of the patent was ASGPR-binding compounds for the degradation of extracellular proteins. And the patent contained the following:

Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described. The experimental process involved the reaction of 2,5-Dichloro-4-(trifluoromethyl)pyrimidine(cas: 785777-98-2).SDS of cas: 785777-98-2

The Article related to asgpr ligand preparation extracellular protein degradation disease therapy, Pharmacology: Effects Of Inflammation Inhibitors and Immune Agents and other aspects.SDS of cas: 785777-98-2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Bohacova, Sona; Ludvikova, Lucie; Postova Slavetinska, Lenka; Vanikova, Zuzana; Klan, Petr; Hocek, Michal published an article in 2018, the title of the article was Protected 5-(hydroxymethyl)uracil nucleotides bearing visible-light photo-cleavable groups as building blocks for polymerase synthesis of photo-caged DNA.Name: 5-(Hydroxymethyl)pyrimidine-2,4(1H,3H)-dione And the article contains the following content:

Nucleosides, nucleotides and 2′-deoxyribonucleoside triphosphates (dNTPs) containing 5-(hydroxymethyl)uracil protected with photo-cleavable groups (2-nitrobenzyl-, 6-nitropiperonyl or 9-anthrylmethyl) were prepared and tested as building blocks for the polymerase synthesis of photo-caged oligonucleotides and DNA. Photo-deprotection (photo-release) reactions were studied in detail on model nucleoside monophosphates and their photoreaction quantum yields were determined Photo-caged dNTPs were then tested and used as substrates for DNA polymerases in primer extension or PCR. DNA probes containing photo-caged or free 5-hydroxymethyluracil in the recognition sequence of restriction endonucleases were prepared and used for the study of photo-release of caged DNA by UV or visible light at different wavelengths. The nitropiperonyl-protected nucleotide was found to be a superior building block because the corresponding dNTP is a good substrate for DNA polymerases, and the protecting group is efficiently cleavable by irradiation by UV or visible light (up to 425 nm). The experimental process involved the reaction of 5-(Hydroxymethyl)pyrimidine-2,4(1H,3H)-dione(cas: 4433-40-3).Name: 5-(Hydroxymethyl)pyrimidine-2,4(1H,3H)-dione

The Article related to hydroxymethyluracil nucleotide preparation photocleavable polymerase photocaged dna, Carbohydrates: Nucleosides and Nucleotides, Cobalamins, Riboflavin and other aspects.Name: 5-(Hydroxymethyl)pyrimidine-2,4(1H,3H)-dione

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia